These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29626277)

  • 1. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
    Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA
    J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
    Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
    Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
    Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying simple linear combination, multiple logistic and factor analysis methods for candidate fecal bacteria as novel biomarkers for early detection of adenomatous polyps and colon cancer.
    Rezasoltani S; Sharafkhah M; Asadzadeh Aghdaei H; Nazemalhosseini Mojarad E; Dabiri H; Akhavan Sepahi A; Modarressi MH; Feizabadi MM; Zali MR
    J Microbiol Methods; 2018 Dec; 155():82-88. PubMed ID: 30439465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
    Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
    Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial.
    You JJ; Liu Y; Kirby J; Vora P; Moayyedi P
    Trials; 2015 Jul; 16():296. PubMed ID: 26156248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
    Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
    Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer.
    Sithambaram S; Hilmi I; Goh KL
    PLoS One; 2015; 10(7):e0131616. PubMed ID: 26158845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
    Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
    Tonus C; Neupert G; Sellinger M
    World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
    Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.
    Rodia MT; Solmi R; Pasini F; Nardi E; Mattei G; Ugolini G; Ricciardiello L; Strippoli P; Miglio R; Lauriola M
    Clin Colorectal Cancer; 2018 Jun; 17(2):e217-e228. PubMed ID: 29352642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
    Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
    Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fecal occult blood test as a tool for improved outpatient qualification for colonoscopy. A single-center experience and 10-year follow-up survey.
    Banaszkiewicz Z; Budzyński J; Tojek K; Jarmocik P; Frasz J; Mrozowski M; Świtoński M; Jawień A
    Adv Med Sci; 2017 Mar; 62(1):171-176. PubMed ID: 28282604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.